Europe
MGB Biopharma announces the completion of its latest funding round.
Orbit Discovery, an Oxford, UK-based biotech company developing an industry-leading peptide discovery platform, are pleased to announce that Dr Mario Polywka has joined their board as a non-executive director.
The trials were the PROVE-HF and EVALUATE-HF trials.
AstraZeneca had a big weekend, with positive results from two separate clinical trial programs causing stock to jump 3.4%.
Lunaphore Technologies S.A. announces the appointment of Joseph E. Bernardo as its new Chairman of the Board of Directors, bringing the total to 5 members.
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The U.S. Food and Drug Administration (FDA) gave tentative approval to Mylan’s pemetrexed, a generic version of Eli Lilly’s $2 billion lung cancer drug, Alimta.
The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.
Bittium Exhibits Its Cardiac Monitoring Products and Solutions at ESC Congress 2019
Akari Therapeutics, Plc announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.
PRESS RELEASES